• Explore /
  • Poster
  • / Phase III study of <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with metastatic pancreatic adenocarcinoma (mPC): Subgroup analysis of Canadian pts from the MPACT trial.

Phase III study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with metastatic pancreatic adenocarcinoma (mPC): Subgroup analysis of Canadian pts from the MPACT trial.

Abstract Poster

Authors

Mustapha Tehfe

Mustapha Ali Tehfe

Hopital Notre Dame de CHUM, Montreal, QC, Canada

Mustapha Ali Tehfe , Scot D. Dowden , Hagen F. Kennecke , Robert Hassan El-Maraghi , Bernard Lesperance , Felix Couture , Richard Letourneau , Darryl Neil Penenberg , Alfredo Romano , Daniel D. Von Hoff

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT00844649

Citation

J Clin Oncol 33, 2015 (suppl 3; abstr 439)

DOI

10.1200/jco.2015.33.3_suppl.439

Abstract #

439

Poster Bd #

E6

Abstract Disclosures

Similar Posters

First Author: David Goldstein

First Author: Dong-Sheng Zhang

First Author: Zev A. Wainberg

First Author: Michele Reni